Evoke Pharma, Eversana

Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI With New Telehealth Solution

SOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced that Evoke, through its wide-scale commercialization partnership with EVERSANA, is launching a telehealth solution for patients.

The new Direct-to-Patient Technology Solution will leverage EVERSANA’s partnership with UpScriptHealth, a direct-to-consumer telehealth platform. The program allows patients who don’t have regular access to care due to their remote location, lack of transportation, affordability, or work schedule to access care via a telehealth option. UpScriptHealth’s telehealth solution provides access to care from a licensed board-certified healthcare provider when it is convenient, generally a same-day appointment with a healthcare provider. This may allow for more rapid consultation and potentially treatment initiation within just a few days, if medically appropriate.

People who have gastroparesis need options to support their ability to obtain relief of their symptoms that are often acute and debilitating. In a recent survey of patients with gastroparesis*:

  • Over half reported their symptoms as being severe or very severe
  • 60% were not satisfied with available treatments for gastroparesis.
  • When asked about their overall medical care, 1 out of 4 reported being dissatisfied.

“This burden and the experience many people have with diabetic gastroparesis has compelled many patients to search for options online. We encourage patients to seek the best option for them, whether that is their own doctor or a motility expert. By offering a telehealth option, we believe we augment current care options and reach an important and significant portion of the diabetic gastroparesis patient population to provide access to care for this difficult disease,” explained Matt D’Onofrio, MBA, Evoke Pharma’s Chief Business Officer.

“This partnership with EVERSANA and UpScriptHealth provides another key channel through which we may meaningfully improve patient access to GIMOTI,” stated Matt D’Onofrio, MBA, Evoke Pharma’s Chief Business Officer. “GIMOTI fills a major treatment gap by providing the current standard of care treatment through a non-oral delivery. Adding direct-to-patient telehealth to the commercial support of the integrated commercial team from EVERSANA expands our ability to address this large and growing market.”

“UpScriptHealth looks forward to initiating this partnership and improving the accessibility of GIMOTI to people suffering from the symptoms of diabetic gastroparesis,” said Peter Ax, Chief Executive Officer and Founder of UpScriptHealth. “We are excited to support Gimoti’s growth and to launch our first integrated solution via our partnership with EVERSANA, the leading provider of global services to the life sciences industry.”

*Yu D, Ramsey FV, Norton WF, Norton N, Schneck S, Gaetano T, Parkman HP. The burdens, concerns, and quality of life of patients with gastroparesis. Dig Dis Sci. 2017 Jan 21. doi: 10.1007/s10620-017-4456-7

About Evoke Pharma, Inc.

Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Visit www.EvokePharma.com for more information.

Follow GIMOTI on Facebook: https://www.facebook.com/GIMOTI-metoclopramide-nasal-spray-104672345100289
Follow Evoke Pharma on Facebook: https://www.facebook.com/Evoke-Pharma-Inc-131313647029724
Follow Evoke Pharma on LinkedIn: https://www.linkedin.com/company/evoke-pharma/

About UpScriptHealth
UpScriptHealth provides a direct-to-consumer Telehealth platform for pharmaceutical companies and consumer products companies allowing for convenient access to high quality health care.  In 2002 we were the first company in the US to be licensed to write prescriptions on the internet through an online physician consultation. Since then we’ve treated more than a million consumers in all fifty states. Learn more at www.UpScriptHealth.com.

About EVERSANA™

EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit EVERSANA.com or connect through LinkedIn and Twitter.

Source: GlobeNewswire